FDA Clears Path for Generic METHERGINE Injections Sans Safety Worries
Published Date: 3/18/2026
Notice
Summary
The FDA has decided that METHERGINE injection wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, as long as they meet all the rules. Patients and healthcare providers can expect more affordable options soon, with no delays caused by safety concerns.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Generics Can Apply to Sell METHERGINE
The FDA determined on March 18, 2026 that METHERGINE (methylergonovine maleate) injection, 0.2 mg/mL, was not withdrawn for reasons of safety or effectiveness. This allows manufacturers to submit abbreviated new drug applications (ANDAs) that refer to this listed drug and may be approved if they meet all other legal and regulatory requirements.
Patients May See Lower-Cost Options Soon
Because the FDA found on March 18, 2026 that METHERGINE (methylergonovine maleate) injection, 0.2 mg/mL, was not withdrawn for safety or effectiveness, generic versions may be approved. Patients and health care providers who use this drug can expect more affordable generic options to become available if ANDA applicants meet approval requirements.
ANDA Applicants May Need Updated Labeling
The FDA said it will continue to list METHERGINE (methylergonovine maleate) injection, 0.2 mg/mL, in the Orange Book's Discontinued Drug Product List but noted that if the Agency determines the drug's labeling should be revised to meet current standards, it will advise ANDA applicants to submit updated labeling. ANDA applicants may therefore need to prepare revised labeling if requested by FDA.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-05308 — Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V BROADWAY GIRL
The government is asking for your thoughts on letting a foreign-built small passenger boat, the M/V BROADWAY GIRL, operate in U.S. coastal waters carrying up to 12 paying passengers. This decision could affect U.S. boat builders and businesses that use American-made vessels. If you want to share your opinion, make sure to comment by April 17, 2026!
Next: 2026-05310 — Certain Chocolate Milk Powder and Packaging Thereof; Issuance of Civil Penalties and Termination of Enforcement Proceeding
Four California companies got hit with big fines—totaling over $5 million—for breaking rules about certain chocolate milk powder and its packaging. These penalties cover violations lasting from 2 to 18 days, and the enforcement case is now officially closed. If you’re in the chocolate milk biz, this is a clear message: follow the rules or pay up!